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A B S T R A C T
Extracellular vesicles (EVs) are involved in several diseases, which have formed the basis
for the potential use of EV analyses in a clinical setting. The protein phenotype of EVs can
provide information on the functionality of the vesicles and may be used for identifica-
tion of disease-related biomarkers.
With this extensive study of 161 healthy individuals it was elucidated that certainmarkers
of plasma EVs are influenced by demographic variations such as gender, age and smoking
status. When the purpose is to use EVs as a diagnostic tool, it should be emphasized how
important it is to choose the correct demographic group when comparing marker levels
of plasma EVs.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Extracellular vesicles (EVs) are a heterogeneous popu-
lation of membrane-enclosed vesicles. EVs are recognized
as important players in cell-to-cell communication and are
described to be involved in numerous biological and
pathological processes. The in vivo role of EVs still remains
elusive, but their presence in several body fluids such as
urine [1], saliva [2], breast milk [3] and plasma [4] suggest
an important role.
The fact that EVs are involved in the development
and progression of several diseases has formed the basis
for the potential use of EV analyses in a clinical setting [5].
The protein profiles and phenotype of EVs can provide
information on the functionality of the vesicles and may
be used for identification of disease-related biomarkers.
The potential of EVs as clinical and noninvasive
biomarkers has already been demonstrated in studies of
various diseases, such as Alzheimer’s [6], systemic lupus
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erythematosus (SLE) [7] and numerous cancer-types:
prostate [8], colorectal [9], ovarian [10] and non-small cell
lung cancer [11].
In order to use EVs in a clinical setting, it is of great im-
portance to know whether the protein phenotype of EVs in
a healthy cohort are dependent on demographic param-
eters such as gender, age or smoking status.
Age is one of the most important risk factors for hu-
man malignancies. At the subcellular level, regular human
aging has been linked to increased genomic instability
[12], global epigenetic changes [13], and altered expres-
sion of genes involved in cell division and extracellular
matrix remodeling [14]. While aging is unavoidable, the
aging mechanism is still unclear because of its complexity
[15]. Smoking causes premature death and is considered
an environmental aging accelerator. The leading causes
of death by smoking are cancer, cardiovascular disease,
and pulmonary disease, which are also known as aging-
related diseases [16].
Both occurrence and development of various diseases
have been seen to vary between the genders, as seen for lung
cancers [17,18], neuro diseases [19], cardiovascular diseases
[20,21], and autoimmune diseases [22] among others. The
higher endogenous estrogen levels in women also seem to
have an influence on the levels of cholesterol, fatty acids and
other lipids. EVs display lipids such as eicosanoids, fatty acids
and cholesterol, organized in a bilayer membrane and is in-
volved in EV-mediated lipid trafficking [23]. Investigation
of differences in protein profiles of plasma EVs between
genders has not previously been reported but it is impor-
tant in order to use the EVs as a diagnostic- or screening
tool for diseases.
The Extracellular Vesicle Array (EV Array) is a sandwich-
ELISA-based method capturing EVs using an antibody-
panel targeting selectedmembrane- ormembrane associated
proteins [24]. The EV Array constitutes a fast, automated,
economical and highly sensitive method for exploration
of plasma-EVs. In this study, we collected plasma from
161 apparently healthy men and women over 40 years
of age and extensively investigated the protein phe-
notypes of the plasma EVs using a panel of 37 markers of
interest. The obtained data were analyzed according to
the demographic parameters of gender, age and smoking
status.
2. Material and methods
2.1. Plasma samples
Venous peripheral blood was obtained from 161 healthy
individuals at Aalborg University Hospital (North Region,
Denmark) using EDTA tubes (Vacuette®, Greiner Bio One,
DE). The collection tubes were centrifuged at 1.800 × g for
6 min at 20 °C and the plasma was collected, mixed to ho-
mogenize, aliquoted and stored at −40 °C until further
analysis.
2.2. Antibodies for production of the EV Array
A total of 37 anti-human antibodies were used and all
are listed in the following with the corresponding clone, if
available: CD146 (P1H12), Flotillin-1, HB-EGF (4G10), HER3
(2F9), HER4 (H4.77.16), Hsp90 (IGF1), N-Cadherin (8C11),
p53 (pAb240), TAG72 (0.N.561), and TSG101 (5B7) from
Abcam (MA, USA); SFTPD (VIF11) from Acris Antibodies
GmbH (DE); EGFR and EGFRvIII from Antibodies-online.com
(DE); CD63 (MEM-259) from Biolegend (CA, USA); HER2
(29D8) from Cell Signalling (MA, USA); CD9 and CD81 from
LifeSpan BioSciences (WA, USA); SPA (6F10) fromNovus Bio-
logicals (CO, USA); CD13 (498001), CD14 (50040), CD142
(323514), CD151 (210127), CD206, CEA (487609), MUC1
(604804), TNF RI, TNF RII and Tspan8 (458811) from R&D
Systems (MN, USA); AREG (S-13), EpCam (0.N.277), Mucin16
(X306), NY-ESO-1 (E978) and PLAP (8B6) from Santa Cruz
Biotechnologies (TX, USA); CD171 from Sigma-Aldrich (MO,
USA); c-MET (016) and PD-L1 from Sino Biological Inc.
(China); and CD163 (Mac2-158) from Trillium Diagnos-
tics, LLC (ME, USA).
2.3. EV Array analysis
Microarray slides were produced using a Spotbot®
Extreme Protein Edition Microarray Printer assembled with
a 946MP4 pin (ArrayIt Corporation, CA, USA) and epoxy-
coated slides (SCHOTT Nexterion, DE) as described by
Jørgensen et al. [25]. The antibodies were diluted with PBS,
added 5% glycerol and printed in triplicates at 75–200 μg/mL
together with positive (100 μg/mL biotinylated human IgG
containing 5% glycerol) and negative (PBS containing 5% glyc-
erol) controls.
The EV Array analysis was performed as described by
Jørgensen et al. [24]. The microarray slides were initially
blocked (50 mM ethanolamine, 100 mM Tris, 0.1% SDS, pH
9.0) prior to incubation with 10 μL plasma sample diluted
(1:10) in wash-buffer (0.05% Tween®20 in PBS). The incu-
bation was performed inMulti-Well Hybridization Cassettes
(ArrayIt Corporation) at RT for two hours followed by over-
night incubation at 4 °C. Following a short wash, the slides
were incubated with a cocktail of biotinylated detection
antibodies (anti-human-CD9, -CD63 and -CD81, LifeSpan
BioSciences, WA, USA) diluted 1:1500 in wash-buffer for
two hours at RT. After a wash, a subsequent 30-minute
incubation step with Cy5-labelled streptavidin (Life Tech-
nologies) diluted 1:1500 in wash-buffer was carried out
for detection. Prior to scanning, the slides were washed
first in wash-buffer, then in deionized water and finally
dried using a Microarray High-Speed Centrifuge (ArrayIt
Corporation).
Scanning and spot detection were performed using an
Innoscan 710AL scanner (Innopsys, Carbonne, FR) as pre-
viously described by Jørgensen et al. [24].
2.4. Data and statistical analysis
Graphs and statistics were carried out using GraphPad
Prism (version 6.04, GraphPad Software, Inc., San Diego,
CA, USA) and Excel (version 2013, Microsoft, Redmond,
WA, USA). Heat maps and Hierarchical cluster analysis
were produced using Genesis (version 1.7.6, IGB TU
Graz, Graz, Austria). Unpaired non-parametric t-test for
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differences between groups was applied and differences
were considered statistically significant, when p < 0.05 (*).
Unless otherwise specified, the data are presented as mean
SD.
3. Results
The EV Array analysis was performed on 161 plasma
samples from healthy individuals. The cohort represented
bothmales and females categorized as either smoker or non-
smoker (never smoked). It was selected to include individuals
with ages ranging from 40 to 70 years, and the demographic
distribution is shown in Table 1.
Thirty-seven different antibodies were printed in
triplicates and used for the analysis of EVs in 10 μL of
unpurified plasma. The protein profiles of the EVs (defined
as positive for CD9, CD63 and/or CD81) revealed a high
variety of expression among the individuals (Fig. 1), which
was also seen in previous studies of healthy individuals
[24,25]. The hierarchical cluster analysis also showed co-
variance among certain markers, e.g. the tetraspanins CD9,
CD81 and CD151, whereas the levels of another tetraspanin,
CD63, showed co-variance with other markers. The cluster
analysis of the individuals revealed several co-varying
groups, but none of them seems to correlate to a specific
demographic type (Fig. 1, left side).
The log2 transformed signal values were used for a com-
prehensive statistical analysis and includedmore than 6.000
data points obtained from approximately 18.000microarray
spots from where 1147 comparisons (t-tests) were gener-
ated (summarized in Table 2).
In general, no differences in the plasma EV profiles were
observed according to gender when all individuals are in-
cluded (Table 2, Row 1). When looking at smoking status
in general the levels of plasma EVs expressing CD9 and
CD151 were found to be increased (Fig. 2); however, this
was not seen for CD81 (Table 2) even though these
tetraspanins were found to cluster (Fig. 1). When compar-
ing the influence of smoking in general (all individuals) only
EpCAM (Epithelial cell adhension molecule) was found to
be decreased in smokers.
Although no significant differences were observed in EVs
according to gender, differences occurred when allocating
the gender cohorts with regard to their smoking status
(Fig. 3). It was found that EVs from male smokers carried
a higher level of CD171 (L1CAM), PD-L1 (Programmed death-
ligand 1) and TSG101 (Tumor susceptibility gene 101) than
the group of female smokers. The tendency of increased
levels in smoking males was also seen when comparing to
the group of non-smoking males. For females the EV level
of TSG101 was seen to be significantly decreased in the
group of smokers.
As described, the influence of smoking on the EV pro-
files were found to be different between the genders. The
level of several proteins was found to be significantly de-
creased in female smokers, whereas this was not seen for
male smokers (Table 2). The reduction was most pro-
nounced for AREG (amphiregulin), MUC1 (CA15-3), CD146
(MUC18), the alanine aminopeptidase CD13 and TSG101
(Fig. 4).
To test whether the level of plasma EVs and their pro-
teins changes during aging the cohort was divided into
three groups (ages 40–49, 50–59 and 60–69). The EV level
of the estrogen receptor AREG was generally found to de-
crease with aging (Fig. 5). This tendency was seen for both
genders, but was only found to be statistical significant
for males. The group of males also showed a reduction in
the EV level of MUC1 during aging, which was not seen
for females.
4. Discussion
Circulating EVs are a promising biomarker source in
various diseases. So far, only a limited number of studies
have examined the diagnostic potential of EVs [11,26]. For
all types of diagnostics it is important to determine the di-
versity of the reference group(s). These reference individuals
could be either carrying a benign type of the disease or other
related diseases. For the purpose of screening for diseases,
a healthy cohort will be the reference group, and hence it
is of great importance to know the diversity of such a healthy
cohort.
Currently, no proteins are known to be constitutively
sorted into vesicles independently of the subcellular origin
and the activation status of the producing cell. In this study
we used a cocktail of antibodies against CD9, CD63 and CD81
to detect the captured EVs. These markers are considered
general exosomal markers [27–29], which are the vesicle
type of primary interest in this study. Also, the EV Array
catches mainly vesicles in the exosomal size-range [24];
hence it is relevant to use detection antibodies aiming for
these vesicles.
The protein profiles of 37 different markers obtained
from the EV Array from the 161 healthy individuals tes-
ted showed a high degree of variation, both with regard
to amount of markers/antigens, but also the number
of different antigens present (Fig. 1). The considerable
heterogeneity in the expression levels of individual markers
in healthy individuals has previously been presented
[24,25]. The hierarchical cluster analysis showed co-
variance among certain markers, e.g. CD9, CD81 and CD151.
The co-variance of these tetraspanins was also found in
lung disease patients and patients with non-small cell lung
Table 1
Demographic characteristics of the 161 included individuals according to
gender, smoking status and age.
Female Male
All individuals 71 90
Non-smokers 48 62
Age 40–49 19 25
Age 50–59 17 25
Age 60–69 12 12
Smokers 23 28
Age 40–49 10 8
Age 50–59 7 13
Age 60–69 6 7
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Fig. 1. Hierarchically clustered heatmap summarizing the EV Array data from all individuals. The color coded bar illustrates the relative intensities of each
analyte. To the left are selected demographic data shown. The first column indicates the aging group, second column the smoking status and the third
column the gender.
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Table 2
Summary of the statistical comparisons (t-tests) performed across the various demographic groups. Red indicates an increase of the mean, and green indicates decrease of the mean. Level of significance is
indicated with asterisks, p < 0.05 (*), p < 0.01 (**), p < 0.001 (***).
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cancer (NSCLC) [11]. The expression of CD63 was
considerably lower than CD9 and CD81, and the expres-
sion was seen to co-variate with another group of markers
including TNF RII and Hsp90. Once more, this implies ques-
tioning the use of CD63 as a standard EV marker which is
supported by earlier results obtained with the EV Array
[11,24,25] and other technologies [30–33].
Clustering the EV Array data hierarchical, as illustra-
ted in Fig. 1, no obvious grouping with regards to the
demographical variables of gender, age or smoking status
was seen. Co-variation was seen in a group of markers con-
taining AREG, CD142, CD146, MUC1, Tspan8 and TNF RI. The
statistical comparisons in this group of markers showed sig-
nificant differences with regards to the age of the cohorts
(Table 2). Including bothmales and females, the plasma level
of AREG on EVs was found to be decreased with aging. The
decrease was found not to be significant for females, al-
though a decreasing tendency is observed. AREG is an
estrogen-responsive gene, and its expression has been found
to be increased in a younger cohort (≤45 years) of breast
cancer patients when compared to an elder cohort (≥70
years) [34]. The same tendency is seen in this study with
the amount of AREG carried on EVs, although the de-
crease during aging was found to be more pronounced for
males, whichwas also observed forMUC1 and Tspan8 (Fig. 5,
Table 2). Regarding females, their smoking status seemed
to affect the amount of AREG on EVs more than their aging,
as female smokers were found to have a decreased level
(Fig. 4).
In this study the smoking status was found to effect the
level of CD146 (MUC18) carried on EVs (Fig. 4). Female
smokers were found to have a decreased amount of CD146
on their vesicles compared to non-smoking females, whereas
no significant differences were found in the cohort of males.
CD146 is a transmembrane glycoprotein belonging to the
immunoglobulin superfamily, which is constitutively ex-
pressed in the human endothelium [35]. CD146 is involved
in the control of cell cohesion and the expression has been
observed on endothelial and smooth muscle cells in the
airway wall [36]. A soluble form of CD146 has been iden-
tified by ELISA in plasma of healthy subjects and the
concentration is modulated in inflammatory diseases [37].
Furthermore, its expressionwas observed to be up-regulated
in alveolar macrophages in diseased/inflammatory lungs of
patients with chronic obstructive pulmonary disease (COPD)
and asthma [38]. Comparing these findings of soluble CD146
with the level of CD146 carried by EVs in plasma it could
be speculated that, during the process of smoking-caused
inflammation in the lungs, the cells seem to change the
protein profile of the EVs. This change in the EV profile could
be due to the need for the cells to increase the secretory
amount of soluble CD146. Future studies will need to elu-
cidate why this response to smoking is only observed in
females.
Additionally, CD146 expression has been shown to be
closely associated with advanced stage malignant mela-
noma, prostate, lung and ovarian cancers [39]. For lung
cancer patients (NSCLC) no significant differences were seen
in the levels of soluble CD146 according to gender, age and
smoking status [35], whereas in patients with adenocarci-
noma of the lungs, CD146 expression was more frequently
Fig. 2. Comparison of non-smokers and smokers (both males and females)
and their vesicular expression of CD9, CD151 and EpCAM. Mean ± SD is
shown and significant differences are marked with asterisks, p < 0.05 (*),
p < 0.01 (**).
Fig. 3. Levels of the markers CD171, PD-L1 and TSG101 are shown
for the smoking cohort with respect to gender and for the gender
cohorts with respect to the smoking status. Mean ± SD is shown and
significant differences are marked with asterisks, p < 0.05 (*),
p < 0.01 (**).
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detected in males than females [40]. Accordingly, some
gender variation of the CD146 expression are seen in can-
cerous patients, but the relations to the level of plasma EVs
carrying CD146 still remains to be clarified.
Until now no studies with regard to protein profiles of
plasma EVs and the influence of smoking have been
found. Qazi and coworkers purified exosomes from
bronchoalveolar lavage fluid (BALF) and found major dif-
ferences between the exosomes from patients with
sarcoidosis and healthy individuals [41]. Patients showed
increased numbers of exosomes in their lungs compared
with healthy individuals and had higher levels of MHCI and
II, some tetraspanins and hsp70. Taken together, the data
from Qazi and coworkers suggests that exosomes may con-
tribute to the inflammatory state of sarcoidosis [41]. They
found no significant differences in total exosomal protein
(μg/ml) between non-smokers and smokers of sarcoidosis
patients. However, significantly higher BALF exosome con-
tents were measured in patients compared to healthy
individuals. Whether the exosomes or other EVs can pass
from the BALF to plasma remains unclear; however, since
the levels and contents of exosomes in the BALF are affect-
ed by smoking and lung inflammation, it is expected that
the plasma levels are affected as well.
BALF exosomes from smoking and non-smoking sar-
coidosis patients showed no significant differences in the
expression of HLA-DR, HLA-ABC, CD54, CD63, CD81, CD86,
MUC1, and CD9. But in relation to the non-inflammatory,
healthy individuals, they found that HLA-DR, HLA-ABC, CD9,
CD63, CD81 and CD54 were significantly increased in the
patients [41]. Sarcoidosis is known to cause inflammation
of the lungs, as does smoking. So our findings that the level
of CD9 on EVs are higher in the group of smokers (due to
inflammation) correlates with the results observed by Qazi
and coworkers when comparing inflammatory patients with
non-inflammatory healthy individuals. Cigarette smoke was
found to reduce the amount of CD9 and CD81 present on
the surface of macrophages from COPD patients [42]. It could
then be speculated whether the decrease of CD9 and CD81
on the cell surface could be due to the fact that the
macrophages are diverting/redirecting the molecules to the
surface of EVs instead.
Cigarette smoke contains more than 4000 different
chemicals, most of which are generated during the com-
bustion process in the cigarette [43]. This study has shown
that the level of markers carried by EVs in plasma is greatly
influenced by the smoking status of the individual. However,
the response to smoking was also seen to be influenced by
the gender, as females tend to have lower amount of certain
EV markers whereas males tend to have increased the
amount of other EV markers.
To our knowledge this is the first extensive study of the
protein profiles of plasma EVs on a large cohort of healthy
individuals. With this study we have elucidated that certain
markers of plasma EVs are influenced by demographic varia-
tions such as gender, age and smoking status (as summarized
in Table 2). When the purpose is to use EVs in a clinical
setting, it should be emphasized how important it is to
choose the correct demographic group when comparing
marker levels of plasma EVs.
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Fig. 4. The plasma levels of EVs carrying AREG, MUC1, CD146, CD13 and TSG101 in the gender cohorts divided in non-smokers and smokers. Mean ± SD
is shown and significant differences are marked with asterisks, p < 0.05 (*), p < 0.01 (**).
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